Tilpotide is a dual targeted heavy blood glucose lowering drug.

On May 21, 2024, the official website of the State Food and Drug Administration showed that Lilly’s double target weight-loss hypoglycemic drug Tilpoltide was approved for marketing, which is applicable to adult type 2 diabetes patients who still have poor blood glucose control after receiving metformin and/or sulfonylurea drugs on the basis of diet control and exercise.

Tilpotide integrates the effects of two types of intestinal glucagon – glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) – into one molecule, and is a weekly formulation that is injected once a week.